2023
Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities
Blauvelt A, Gondo G, Bell S, Echeverría C, Schmitt-Egenolf M, Skov L, van de Kerkhof P, Howard L, Strober B. Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities. Journal Of Psoriasis And Psoriatic Arthritis 2023, 8: 100-106. PMID: 39296315, PMCID: PMC11361513, DOI: 10.1177/24755303231160683.Peer-Reviewed Original ResearchPsoriasis Area Severity IndexBody surface area involvementPatient-reported outcome measuresSurface area involvementDisease-specific qualityQuality of lifeExtensive psoriasisPsoriasis severityArea involvementPatient burdenOutcome measuresSevere diseaseClinical experienceSeverity IndexPsoriasisDiseasePresent studyPatientsSeverity
2022
The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry
Lebwohl M, Medeiros R, Mackey R, Harrold L, Valdecantos W, Flack M, Golembesky A, Kotowsky N, Strober B. The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 71-78. PMID: 39296823, PMCID: PMC11361522, DOI: 10.1177/24755303221079814.Peer-Reviewed Original ResearchPlaque psoriasisReal-world evidenceMore treatment experiencePsoriasis RegistryPustular psoriasisTreatment experiencePatient-reported outcome measuresGeneralized pustular psoriasisCurrent treatment optionsFuture treatment decisionsQuality of lifeGPP treatmentNeutrophilic pustulesPatient sociodemographicsMedian painMedication useNorth American adultsSystemic diseaseDisease characteristicsTreatment optionsRecurrent flaresDisease burdenPatient outcomesTreatment decisionsOutcome measures
2019
Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council
Strober B, van de Kerkhof P, Callis Duffin K, Poulin Y, Warren R, de la Cruz C, van der Walt J, Stolshek B, Martin M, de Carvalho A. Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. American Journal Of Clinical Dermatology 2019, 20: 699-709. PMID: 31228013, PMCID: PMC6764927, DOI: 10.1007/s40257-019-00458-2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overClinical Decision-MakingCommunicationCross-Sectional StudiesFeasibility StudiesFemaleHumansInternational CooperationMaleMiddle AgedPatient Reported Outcome MeasuresPhysician-Patient RelationsPsoriasisQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeYoung AdultConceptsPsoriasis Symptom InventoryStatic Physician's Global AssessmentBody surface areaPsoriasis-affected body surface areaSymptom InventoryPatient-reported outcome measuresPatient treatment prioritiesPhysician global assessmentPatient-physician communicationClinical care settingsInternational Psoriasis CouncilPSI total scorePatient-physician relationshipMild psoriasisPsoriasis signsSevere psoriasisUntreated patientsModerate psoriasisDermatology clinicPsoriasis severityPatient visitsSame visitTreatment decisionsCare settingsOutcome measures
2017
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis
Viswanathan H, Mutebi A, Milmont C, Gordon K, Wilson H, Zhang H, Klekotka P, Revicki D, Augustin M, Kricorian G, Nirula A, Strober B. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value In Health 2017, 20: 1174-1179. PMID: 28964451, DOI: 10.1016/j.jval.2016.11.020.Peer-Reviewed Original ResearchConceptsStatic Physician's Global AssessmentDermatology Life Quality IndexPsoriasis Symptom InventorySevere plaque psoriasisBody surface areaPsoriasis signsPlaque psoriasisPsoriasis-affected body surface areaForm Health Survey version 2Global assessmentPatient-reported outcome instrumentsPhysician global assessmentLife Quality IndexMeasurement propertiesElectronic daily diaryPSI total scoreDLQI responsesPASI responsePsoriasis AreaBodily painWeek 12Clinical trialsWeek 8Outcome measuresOutcome instruments
2010
Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial
Bangert C, Strober B, Cork M, Ortonne J, Luger T, Bieber T, Ferguson A, Ecker R, Kopp T, Weise-Riccardi S, Guettner A, Stingl G. Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. Dermatology 2010, 222: 36-48. PMID: 21150167, DOI: 10.1159/000321711.Peer-Reviewed Original ResearchConceptsPimecrolimus cream 1End of studyCream 1Vehicle creamTopical pimecrolimusAD lesionsAtopic dermatitisDouble-blind treatmentDermal dendritic cellsProportion of patientsAtopic dermatitis lesionsNumber of leukocytesAD remissionEczema AreaPlacebo creamSubclinical inflammationTopical corticosteroidsControlled TrialsDendritic cellsInflammatory infiltrateLangerhans cellsNonsignificant reductionSkin biopsiesT cellsOutcome measures
2009
Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study
Strober B, Menon K, McMichael A, Hordinsky M, Krueger G, Panko J, Siu K, Lustgarten J, Ross E, Shapiro J. Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study. JAMA Dermatology 2009, 145: 1262-1266. PMID: 19917955, DOI: 10.1001/archdermatol.2009.264.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultAgedAlefaceptAlopecia AreataDermatologic AgentsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansInjections, IntramuscularMaleMiddle AgedNew York CityProbabilityRecombinant Fusion ProteinsRisk AssessmentSeverity of Illness IndexStatistics, NonparametricTreatment OutcomeYoung AdultConceptsSevere alopecia areataAlopecia areataPlacebo-controlled clinical trialEfficacy of alefaceptPlacebo-receiving groupSevere plaque psoriasisMain outcome measuresPlaque psoriasisPrevious therapyAlopecia ToolClinical trialsAlefaceptOutcome measuresUS FoodDrug AdministrationConsecutive weeksBiologic inhibitorsScalp hairAreataTreatmentWeeksSignificant improvementMulticenterPlaceboPsoriasis
2005
Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study
Strober B, Siu K, Alexis A, Kim G, Washenik K, Sinha A, Shupack J. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. Journal Of The American Academy Of Dermatology 2005, 52: 1082-1084. PMID: 15928633, DOI: 10.1016/j.jaad.2005.03.039.Peer-Reviewed Original ResearchConceptsSevere alopecia areataAlopecia areataAlopecia totalisAlopecia universalisOpen-label pilot studyEfficacy of etanerceptOpen-label studyTNF-alpha inhibitorsPrimary outcome measureEnd of treatmentAlopecia ToolHair regrowthOutcome measuresEtanerceptHealthy adultsAreataContinuous treatmentPilot studySignificant regrowthTotalisTreatmentUniversalisSubjectsSeverityWeeks